-+ 0.00%
-+ 0.00%
-+ 0.00%

AlphaValue/Baader Europe Says Roche's Pipeline Delivery Offers Answers to Upcoming Patent Cliffs

MT Newswires·11/18/2026 00:33:55
Listen to the news
12:33 AM EST, 11/18/2026 (MT Newswires) -- AlphaValue/Baader Europe believes Roche (RO.SW) improved pipeline delivery ahead of anticipated patent cliffs while avoiding "major" research and development setbacks compared with its peers. "The baton from subcutaneous-and-intravenously administered multiple sclerosis market leader Ocrevus (c.11% of sales; exclusivity until 2028-29) should be picked up by oral pill fenebrutinib (expected to be approved in 2027). While the next three-to-five years may also see the haemophilia leader Hemlibra (c.8%) and cancer treatment Tecentriq (c.6%) losing patents, Roche may find solutions in the strong momentum of the blood cancer portfolio, the newly approved breast cancer drug Giredestrant, and the late-stage candidates in Alzheimer's, Parkinson's, MASH, Hypertension and the lucrative obesity space. At the same time, we also acknowledge the risks involved in the late-stage trials in hard-to-crack areas of Alzheimer's and Parkinson's," according to a Tuesday note. Accordingly, the research firm raised the Swiss drugmaker's price target to 414 francs from 388 francs. On the other hand, AlphaValue/Baader Europe said Roche's valuations offer no room for material upside, adding that "waiting for sentiment-driven corrections seems like a good idea to play Roche." The stock has a reduce rating at the research firm.